Drug Trial Radar · NCT00866970
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
Last checked: Nov 20, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Sep 2008
Primary completion
Aug 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Mar 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).
Conditions
- NSCLC
- Fatigue
- Cachexia
Interventions
ALD518Biological
ALD518 80 mg on Day 1, Week 8 and Week 16
ALD518Biological
ALD518 160 mg IV on Day 1, Week 8 and Week 16
ALD518Biological
ALD518 360 mg IV on Day 1, Week 8, and Week 16
Infusion of 0.9% Saline without ALD518Biological
Infusion of 0.9% Saline without addition of ALD518
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Safety parameters.Time frame: 20 weeks
Locations
43 sites in 9 countries. Site status is shown where the registry gives one.
Rivercity Hospital Research Centre
Auchenflower, Queensland, Australia
Australian Clinical Research Organisation
Kippa-Ring, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Palliative Care Launceston General Hospital
Launceston, Tasmania, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada
McGill University, Department of Oncology
Montreal, Quebec, Canada
A. Gvamichava National Cancer Centre
Tbilisi, Georgia
Union Cancer Prevention Centre
Tbilisi, Georgia
Medulla Chemotherapy and Immunotherapy Clinic
Tbilisi, Georgia
Kidwai Memorial Institute of Oncology
Bangalore, India
Kailash Cancer Hospital and Research Centre
Gujarat, India
IndoAmerican Cancer Institute & Research Center
Hyderabad, India
SEAROC Cancer Centre
Jaipur, India
Orchid Nursing Home
Kolkata, India
Tata Memorial Hospital
Mumbai, India
Shatabdi Hospital
Mumbai, India
Mahavir Cancer Sansthan
Patna, India
Jehangir Clinical Development Centre Pvt. Ltd.
Pune, India
Indira Gandhi Institute of Medical Sciences
Patna, Bihar, India
Dr. Kamakshi Memorial Hospital
Pallikaranai, Chennai, India
GKNM Hospital
Pappanaickenpalayam, Coimbatore, India
Curie Manavata Cancer Centre
Nashik, Maharashtra, India
P3 Research LTD
Tauranga, New Zealand
Oddzial Chorob Pluc i Leczenia Raka Pluc
Bydgoszcz, Poland
Oddzial Chemioterapii Szpital Morski
Gdynia, Poland
II Oddzia Chorob Pluc z Pododdzialem Chemioterapii
Krakow, Poland
Oddzial II Chemioterapii Specjalistyczny Szpital
Szczecin, Poland
Professor Dr. Al Trestioreanu Institute
Bucharest, Romania
Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy
Cluj-Napoca, Romania
Oradea Clinical County Hospital Medical Oncology Department
Oradea, Romania
County Hospital Sibiu Medical Oncology Department
Sibiu, Romania
City Clinical Hospital No. 1
Novosibirsk, Russia
Saint-Petersburg State Medical University, I.P. Pavlov
Saint Petersburg, Russia
St. Petersburg City Oncology Dispensary
Saint Petersburg, Russia
Yaroslavl Regional clinical Oncology Hospital
Yaroslavl, Russia
Republic Oncology Dispensary
Ufa, Bashkortostan Republic, Russia
Territorial Clinical Oncology Dispensary
Krasnodar, Krasnodar Territory, Russia
Stavropol Territorial Clinical
Pyatigorsk, Stavropol Territory, Russia
Institute of Lung Diseases and TB
Belgrade, Serbia
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.